Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q4 EPS of ($0.54), $0.29 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• HSBC Upgrades Bid Corp Ltd (BID:SJ) to Buy
• UBS Downgrades Zhaojin Mining Industry Co Ltd (1818:HK) to Neutral